Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-08-24 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2022年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2022 by Shenzhen BGI Genomics Co., Ltd. It contains specific financial data such as beginning balances, cumulative amounts, interest, repayments, and ending balances for various related parties and subsidiaries. The presence of half-year period data and substantive financial figures indicates this is a financial report for a period shorter than a full fiscal year. There is no indication that this is an announcement or a certification, nor is it a full annual report or earnings release. The content aligns with an Interim / Quarterly Report (IR) due to the half-year period and detailed financial data provided. H1 2022
2022-08-24 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳华大基因股份有限公司 2022 年半年度报告全文" which translates to "BGI Genomics Co., Ltd. 2022 Semi-Annual Report Full Text." It explicitly states it is a half-year report for the period January 1, 2022 to June 30, 2022. The content includes detailed financial data, management discussion and analysis, company overview, financial indicators, and other comprehensive sections typical of an interim or quarterly report. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-24 Chinese
2022年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022 Semi-Annual Special Report on the Deposit and Use of Raised Funds" by Shenzhen BGI Genomics Co., Ltd. It details the use and management of funds raised through a specific share issuance, including amounts raised, usage, investment projects, and compliance with regulatory guidelines. The content focuses on the management and actual use of capital raised, including investment projects and financial details related to the raised funds. It is a specialized report on fundraising and capital usage rather than a general financial report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is over 12,000 characters and contains detailed financial data about the raised funds, so it is not merely an announcement or a certification. Therefore, the appropriate classification is CAP.
2022-08-24 Chinese
第三届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen BGI Genomics Co., Ltd. It details the meeting held on August 23, 2022, where the board reviewed and approved the 2022 semi-annual report and related fundraising usage reports. The document does not contain the actual semi-annual report or detailed financial statements but rather announces the approval and disclosure of these reports on external platforms. The document length is short (1175 characters) and primarily serves as an official announcement of meeting resolutions and report approvals. Therefore, it fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement rather than the report itself or a detailed financial report.
2022-08-24 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2022年半年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年半年度募集资金存放与使用情况的专项核查报告" which translates to a "Special Inspection Report on the Deposit and Use of Raised Funds for the Half Year 2022." It is issued by the sponsor (中信证券股份有限公司) for 深圳华大基因股份有限公司. The content details the use, management, and verification of funds raised through a specific stock issuance, including detailed financial figures, project investment progress, and compliance with regulatory requirements. It includes a thorough review and audit of the raised funds usage for the half-year period ending June 30, 2022. This is a specialized audit or verification report focusing on the use of raised capital, not a full annual or interim financial report. It is not an announcement or a brief summary but a detailed report with financial data and audit conclusions. Therefore, it fits best under the category of Audit Report / Information (AR). H1 2022
2022-08-24 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 年半年度报告摘要' which translates to '2022 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also includes shareholder information and management discussion references. The document length is 3569 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. The content aligns with a comprehensive interim or quarterly financial report rather than a brief summary or announcement. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.